Syncona : OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechs


British Patient... | May 15, 2023

Related Keywords

United Kingdom ,British ,James Jim Geraghty ,Jim Geraghty ,Genzyme Europe ,Ros Deegan ,Carol Robinson ,Rosamond Deegan ,Linkedin ,Yale Law School ,Oxford Science Enterprises ,Canbridge Pharmaceuticals ,Business Development At Sanofi ,Twitter ,Prudential Regulation Authority ,British Patient Capital ,Consilium Strategic Communications ,Financial Conduct Authority ,British Business Bank ,Pieris Pharmaceuticals ,Independent Director ,Patient Capital ,Northpond Ventures ,Sanofi Ventures ,Lewis La Torre ,Future Fund ,Non Executive Director ,Orchard Therapeutics ,Voyager Therapeutics ,Fulcrum Therapeutics ,Third Rock Ventures ,Senior Vice President Strategy ,Business Development ,Orphan Drug Revolution ,Chief Executive Officer Phone ,Kumail Waljee Phone ,British Patient ,Patient Capital Limited ,Business Bank ,Syncona Limited Stock Exchange ,News ,Information ,Press Release ,Rim ,Geraghty ,Coins ,Us ,Independent ,Director ,End ,Ringing ,Nternational ,Experience ,Rom ,Enzyme ,Bed ,Hair ,F ,Multiple ,Isted ,Ritish Bact Gg00b8p59c08 ,